Low rate of lymphedema after extended pelvic lymphadenectomy followed by pelvic irradiation of node-positive prostate cancer

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Rasmusson, Elisabeth ^a   Gunnlaugsson, Adalsteinn ^a   Blom, René ^a   Björk Eriksson, Thomas ^b   Nilsson, Per ^a   Ahlgen, Göran ^a   Jönsson, Charlotta ^a   Johansson, Karin ^a   Kjellén, Elisabeth ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Lymphadenectomy; Lymphedema; Node positive; Pelvic irradiation; Prostate cancer

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CLINICAL ARTICLE; DEFECATION URGENCY; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; FECES INCONTINENCE; FOLLOW UP; HUMAN; INCIDENCE; LEG; LEG SWELLING; LYMPHEDEMA; MALE; MULTIMODALITY CANCER THERAPY; PELVIC PAIN; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PREVALENCE; PROCTITIS; PROSTATE; PROSTATE CANCER; RADIATION DOSE; RECTUM HEMORRHAGE; SEMINAL VESICLE; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE;

AGED; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHEDEMA; MALE; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; STOCKINGS, COMPRESSION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887686443     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-271     Document Type: Article

References (27)

1. Keegan KA, Cookson MS. Complications of pelvic lymph node dissection for prostate cancer. Curr Urol Rep 2011, 12(3):203-8. 10.1007/s11934-011-0179-z, 21394597.
2. Pilepich MV, et al. Treatment-related morbidity in phase III RTOG studies of extended-field irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984, 10(10):1861-7. 10.1016/0360-3016(84)90263-3, 6386761.
3. Beesley V, et al. Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. Cancer 2007, 109(12):2607-14. 10.1002/cncr.22684, 17474128.
4. Bergmark K, et al. Lymphedema and bladder-emptying difficulties after radical hysterectomy for early cervical cancer and among population controls. Int J Gynecol Cancer 2006, 16(3):1130-9. 10.1111/j.1525-1438.2006.00601.x, 16803496.
5. Achouri A, et al. Complications of lymphadenectomy for gynecologic cancer. Eur J Surg Oncol 2013, 39(1):81-6. 10.1016/j.ejso.2012.10.011, 23117018.
6. Ryan M, et al. Aetiology and prevalence of lower limb lymphoedema following treatment for gynaecological cancer. Aust N Z J Obstet Gynaecol 2003, 43(2):148-51. 10.1046/j.0004-8666.2003.00040.x, 14712972.
7. Ladjevardi S, et al. Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20-100 ng/mL. BJU Int 2012, Epub.
8. Akre O, et al. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol 2011, 60(3):554-63. 10.1016/j.eururo.2011.05.047, 21664039.
9. Daneshmand S, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004, 172(6 Pt 1):2252-5.
10. Engel J, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010, 57(5):754-61. 10.1016/j.eururo.2009.12.034, 20106588.
11. Briganti A, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN + prostate cancer: results of a matched analysis. Eur Urol 2011, 59(5):832-40. 10.1016/j.eururo.2011.02.024, 21354694.
12. Briganti A, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N + patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009, 55(2):261-70. 10.1016/j.eururo.2008.09.043, 18838212.
13. Sabolch A, et al. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 2011, 81(4):e351-60. 10.1016/j.ijrobp.2011.01.063, 21493015.
14. Galalae RM, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58(4):1048-55. 10.1016/j.ijrobp.2003.08.003, 15001244.
15. Pistis F, et al. External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy 2010, 9(1):15-22. 10.1016/j.brachy.2009.05.001, 19734106.
16. Koukourakis G, et al. Brachytherapy for prostate cancer: a systematic review. Adv Urol 2009, 327945. Epub.
17. Phan TP, et al. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 2007, 177(1):123-7. discussion 127, 10.1016/j.juro.2006.08.109, 17162020.
18. Hoskin PJ, et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007, 84(2):114-20. 10.1016/j.radonc.2007.04.011, 17531335.
19. Hoskin PJ, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012, 103(2):217-22. 10.1016/j.radonc.2012.01.007, 22341794.
20. Bittner N, et al. Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?. Int J Radiat Oncol Biol Phys 2010, 76(4):1078-84. 10.1016/j.ijrobp.2009.02.069, 19553031.
21. Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007, 52(1):29-37. 10.1016/j.eururo.2007.04.020, 17448592.
22. Sander AP, et al. Upper-extremity volume measurements in women with lymphedema: a comparison of measurements obtained via water displacement with geometrically determined volume. Phys Ther 2002, 82(12):1201-12.
23. Nuutinen J, Ikaheimo R, Lahtinen T. Validation of a new dielectric device to assess changes of tissue water in skin and subcutaneous fat. Physiol Meas 2004, 25(2):447-54. 10.1088/0967-3334/25/2/004, 15132310.
24. Warde P, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011, 378(9809):2104-11. 10.1016/S0140-6736(11)61095-7, 3243932, 22056152.
25. Marks LB, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S10-9.
26. Bentzen SM, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S3-9. 3431964, 20171515.
27. Salomon G, et al. Importance of baseline potency rate assessment of men diagnosed with clinically localized prostate cancer prior to radical prostatectomy. J Sex Med 2009, 6(2):498-504. 10.1111/j.1743-6109.2008.01089.x, 19143908.